Condition

Refractory Cancer clinical trials and research

• 18Clinical trials
• 1NIH research projects
• 14Countries

Newest Refractory Cancer clinical trials

All recruiting trials (18)

• CBA-1535 (5T4/CD3) T‑cell engager given alone and with pembrolizumab for advanced solid tumors

  This trial tests whether CBA-1535, a T‑cell engager that targets 5T4, is safe and shows early signs of benefit when given alone or with pembrolizumab to people with advanced solid tumors who have no standard treatment options.

  Recruiting at 2 sites Phase 1 Chiome Bioscience Inc. · Nagaizumicho, Shizuoka and 1 other locations · NCT07016997

• Investigating a new cancer treatment for relapsed or refractory B-cell malignancies

  This study is testing a new cancer drug called BGB-16673 combined with other treatments to see if it can help people with tough-to-treat B-cell cancers feel better.

  Recruiting at 49 sites Phase 1/2 BeOne Medicines · Phoenix, Arizona and 48 other locations · NCT06634589

• Outpatient teclistamab treatment plan for relapsed or refractory multiple myeloma

  This pilot will try giving teclistamab to adults with relapsed or refractory multiple myeloma in an outpatient clinic to see if it can be delivered safely and practically while measuring effects on caregivers.

  Recruiting Phase 4 University Health Network, Toronto · Toronto, Ontario · NCT06251076

• Targeted therapies for childhood and adolescent cancer

  This study is testing if new targeted treatments based on the genetic makeup of tumors can help kids and teens with cancer feel better and improve their chances of recovery.

  Recruiting at 12 sites Phase 1/2 Australian & New Zealand Children's Haematology/Oncology Group · Newcastle, New South Wales and 13 other locations · NCT06208657

• Testing a new treatment for advanced cancer using a radiolabeled drug

  This study is testing a new drug for adults with advanced cancer who have run out of other treatment options to see if it is safe and how well it works.

  Recruiting at 2 sites Phase 1/2 Spago Nanomedical AB · Adelaide, South Australia and 1 other locations · NCT06184035

• Using modified T cells to treat relapsed head and neck cancer

  This study is testing a new treatment using modified immune cells to see if it can help people with relapsed head and neck cancer feel better and improve their outcomes.

  Recruiting Phase 1 UNC Lineberger Comprehensive Cancer Center · Chapel Hill, North Carolina · NCT06096038

• Treatment for recurrent and refractory solid tumors using IMA402

  This study is testing a new treatment called IMA402 to see if it can help people with advanced solid tumors that haven't responded to other therapies.

  Recruiting at 24 sites Phase 1/2 Immatics Biotechnologies GmbH · Heidelberg, Baden-Wurttemberg and 28 other locations · NCT05958121

• MQ710 with or without pembrolizumab for advanced skin and other solid tumors

  This will test different doses of MQ710, alone or together with pembrolizumab, in adults with advanced or recurrent solid tumors (including skin cancers) to find a safe dose with mild side effects.

  Recruiting at 5 sites Phase 1 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT05859074

• Evaluating a new treatment for advanced solid tumors

  This study is testing a new treatment called ADU-1805 for people with advanced solid tumors to see how safe it is and how well it works on its own and with another drug.

  Recruiting at 11 sites Phase 1 Sairopa B.V. · Detroit, Michigan and 10 other locations · NCT05856981

• Combination therapy for relapsed large cell lymphoma using epcoritamab and chemotherapy

  This study is testing a new combination of treatments for people with relapsed large cell lymphoma to see if it helps them respond better after previous therapies.

  Recruiting at 4 sites Phase 2 Hoosier Cancer Research Network · Indianapolis, Indiana and 3 other locations · NCT05852717

• Combining zanubrutinib and pemetrexed for treating relapsed or refractory CNS lymphomas

  This study is testing if combining two medications, zanubrutinib and pemetrexed, can help people with relapsed or stubborn central nervous system lymphomas feel better and live longer.

  Recruiting Phase 2 Baptist Health South Florida · Miami, Florida · NCT05681195

• GV20-0251 treatment for advanced solid tumors

  This study is testing a new treatment called GV20-0251 for people with advanced solid tumors that haven't improved with standard treatments, to see how safe it is and if it works better when combined with another medication.

  Recruiting at 10 sites Phase 1/2 GV20 Therapeutics · Los Angeles, California and 12 other locations · NCT05669430

• Precision medicine for children with cancer

  This study is testing if personalized medicine can improve treatment and outcomes for children with different types of cancer in Australia and New Zealand.

  Recruiting at 10 sites Australian & New Zealand Children's Haematology/Oncology Group · Adelaide and 10 other locations · NCT05504772

• Allogeneic CAR T-cell therapy for advanced cancers

  This study is testing a new type of immune cell therapy for people with advanced cancers to see if it can safely target and attack their tumors better than traditional treatments.

  Recruiting Phase 1 CytoMed Therapeutics Pte Ltd · Singapore · NCT05302037

• Combining pembrolizumab and bendamustine for treating relapsed Hodgkin lymphoma

  This study is testing whether combining two drugs, pembrolizumab and bendamustine, can help people with relapsed Hodgkin lymphoma feel better and improve their treatment outcomes.

  Recruiting Phase 2 University Health Network, Toronto · Toronto, Ontario · NCT04510636

• Combination therapy for recurrent primary central nervous system lymphoma

  This study is testing a new combination of three medications to see if it can help people with recurrent primary central nervous system lymphoma feel better after their previous treatments didn't work.

  Recruiting at 3 sites Phase 1/2 Dana-Farber Cancer Institute · Boston, Massachusetts and 3 other locations · NCT04421560

• Using omeprazole to enhance treatment for advanced prostate cancer

  This study is testing if adding omeprazole to taxane treatments can help men with advanced prostate cancer who haven't responded to these therapies before.

  Recruiting at 2 sites Phase 2 Wake Forest University Health Sciences · Salisbury, North Carolina and 1 other locations · NCT04337580

• Treatment for recurrent and refractory solid tumors using engineered T-cells and nivolumab

  This study is testing a new treatment using specially designed T-cells and a drug called nivolumab to see if it can help people with tough-to-treat solid tumors.

  Recruiting at 21 sites Phase 1/2 Immatics US, Inc. · Stanford, California and 20 other locations · NCT03686124

NIH-funded research (1)

Early-stage science funded by the US National Institutes of Health. Most of these projects don't enroll patients, but they show what is being worked on.

• A tool to match children with relapsed cancer to clinical trials

  This study is creating a helpful tool called GEARBOx that makes it easier for kids with tough-to-treat cancers, like certain types of leukemia, to find and join clinical trials that could help them, by using important genetic information to match them with the right options.

  NIH research University of Chicago · Chicago, United States · NIH-10923956

Related topics

Quick answers

How many Refractory Cancer clinical trials are recruiting right now?

18, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 14 countries. The most sites are in United States (10 trials), Australia (4 trials), Canada (3 trials), Germany (3 trials), New Zealand (2 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 1/2: 7, Phase 1: 5, Phase 2: 4, Phase 4: 1. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →